Page contentsPage contents Key facts Decision Key facts Active substance surabgene lomparvovec Therapeutic area Eye disorders Decision number EMA/PE/0000232939 PIP number EMA/PE/0000232939 Pharmaceutical form(s) Suspension for injection Condition(s) / indication(s) Treatment of diabetic retinopathy Route(s) of administration Suprachoroidal space injection Contact for public enquiries Abbvie LimitedEmail: paediatricteam@abbvie.com Tel: +44(0) 1628925033 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 19/03/2025 Compliance check done No Decision EMA/PE/0000232939: EMA decision of 19 March 2025 on the granting of a product specific waiver for surabgene lomparvovecAdopted Reference Number: EMADOC-1700519818-1953684 English (EN) (235.26 KB - PDF)First published: 17/06/2026 View Share this page